Product Description
Our lead candidate for AlzheimerÕs disease, CT1812, is designed to displace A_ oligomers from their binding sites and has shown early clinical evidence that it improves biomarkers of the disease and may improve cognition in symptomatic patients. (Sourced from: https://cogrx.com/ct1812-mimics-protective-genetic-mutation/)
Mechanisms of Action: PGRMC1 Antagonist, S2R Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Cognition
Company Location: Eastern America
Company Founding Year: 2014
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Czech Republic, Netherlands, Spain, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Cognition presented P2 Alzheimer Disease results on 2026-11-19 for Zervimesine
- Clinical Outcomes Expected - Cognition announced they will present P2 Alzheimer Disease results in 2H27 for Zervimesine
- Clinical Trial Start Expected - Cognition announced they will initiate a P3 Lewy Body Dementia trial in 3Q27 for Zervimesine
Highest Development Phases
Phase 2: Alzheimer Disease|Dementia|Early Alzheimer Disease|Lewy Body Dementia|Lewy Body Disease|Mild-Moderate Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05531656 |
COG0203 | P2 |
Active, not recruiting |
Alzheimer Disease|Early Alzheimer Disease |
2027-05-31 |
43% |
2026-08-11 |
|
NCT05225415 |
COG1201 | P2 |
Completed |
Lewy Body Disease|Dementia|Lewy Body Dementia |
2024-11-25 |
45% |
2025-05-16 |
|
NCT03507790 |
COG0201 | P2 |
Completed |
Alzheimer Disease|Mild-Moderate Alzheimer Disease |
2024-05-29 |
40% |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
2022-002326-27 |
Clinical Trial of CT1812 in Mild to Moderate Alzheimerâs Disease | P2 |
Completed |
Alzheimer Disease|Mild-Moderate Alzheimer Disease |
2024-05-29 |
40% |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/07/2026 |
News Article |
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference |
|
03/31/2026 |
News Article |
Cognition Therapeutics CEO Issues Letter to Shareholders |
|
03/23/2026 |
News Article |
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results |
|
03/17/2026 |
News Article |
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 |
